343 kinds of medicines officially passed the formal examination is expected to be included in the National Medical Insurance Drug List
From September 6th to 12th, the National Medical Security Administration announced the list of declared drugs that passed the preliminary formal review for the adjustment of the National Medical Insurance Drug List in 2022. Recently, according to feedback from various parties Opinions, the relevant drugs were reviewed and the results were revised according to the procedures. On September 17, the National Medical Insurance Bureau officially announced the "List of Drug Lists that Have Passed Formal Examination for National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance in 2022". A total of 343 drugs have officially passed the formal examination.
Swipe up and down to open the big picture to view the list of medicines , among which includes 198 kinds of western medicines and Chinese patent medicines outside the catalogue, such as the first domestically produced novel coronavirus pneumonia oral medicine azvudine tablets, and 145 kinds of western medicines and Chinese patent medicines in the catalogue such as adalimumab injection , compared with the declarations that passed the preliminary formal examination Among the 344 kinds of drugs in the list of drugs, one western drug, metronidazole vaginal expansion suppository, was reduced.
In the context of the normalization of the prevention and control of the new crown epidemic, since the first implementation of the self-reporting system for enterprises in the medical insurance drug catalog in 2020, the National Medical Insurance Administration has attached great importance to the treatment of new coronary pneumonia. As one of the application conditions, a batch of drugs for the treatment of new coronary pneumonia has been included in the list of medical insurance drugs. The National Medical Insurance Administration stated that during this application process, for the new coronary pneumonia treatment drugs that have been declared and passed the formal review, follow-up work will be carried out according to procedures, and strive to be officially included in the medical insurance catalog at a reasonable price. A variety of rare disease drugs have passed the formal review. In July, the National Medical Insurance Administration stated that there is no time limit for the application of the medical insurance catalogue for rare disease drugs "approved for marketing after January 1, 2017". As early as this year, when the negotiation of the medical insurance catalogue was launched, the National Medical Insurance Administration made it clear that the medical insurance catalogue would appropriately tilt to special groups such as rare disease patients and children. The list of drugs that passed the formal review this time includes a number of rare disease drugs, such as Spinal Muscular Atrophy (SMA) drug Risprom Oral Solution Powder, and Type I Gaucher's Disease Drug Imigide for Injection Enzyme, type Ⅰ mucopolysaccharidosis specific drug for injection Laronidase concentrated solution, Pompe disease treatment drug injection alglucosidase, etc. The next step is to organize expert review and other work according to procedures. The National Medical Insurance Bureau stated that the adjustment of the medical insurance drug list is divided into enterprise application, formal review, expert review, negotiation and bidding, etc. Formal review is only one of them. Passing the formal review indicates that the drug is eligible to enter the next step of expert review. Only after successfully passing all the links of the list adjustment can it be finally included in the National Medical Insurance Drug List. In the next step, the National Medical Insurance Administration will organize expert reviews according to the requirements of the "Interim Measures for Medication Management of Basic Medical Insurance " and the "2022 Work Plan for the Adjustment of Drug Catalogues for National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance". Work. If progresses smoothly, a new version of the medical insurance drug catalog will be announced in November, and will be implemented on January 1 next year. Since its establishment in 2018, the National Medical Insurance Administration has always attached great importance to the management of the medical insurance drug catalog, and the access method of the medical insurance drug catalog has undergone major reforms. Through the establishment of a dynamic adjustment mechanism for the medical insurance drug list, the adjustment period has been greatly shortened from 8 years, the longest in the past, to one year. A total of 507 new and good drugs have been included in the past 4 years, and 391 drugs with uncertain curative effects have been recalled. The current version of the medical insurance list Western medicine and Chinese medicine The number of patent medicines increased to 2,860. The shortcomings of oncology drugs, chronic diseases, rare diseases, and children's drugs have been gradually filled. The structure and efficacy of drugs in the medical insurance catalog have been greatly optimized. The drug guarantees in most therapeutic areas have been synchronized with the international ones, and the guarantee capacity has been significantly improved. Among them, 250 drugs were included through price negotiationFor medical insurance, many "high-priced drugs" talk about "popular prices", and most of the medicines have obtained the lowest prices in the world, with an average price reduction of over 50%.
The client of Hubei Daily, which pays attention to major events in Hubei and the world, not only pushes authoritative policy interpretations, fresh hot information, practical and convenient information for users, but also launches a series of special functions such as palm reading, reporting, learning, and online interaction. .
